The Failure of US Cannabis Policy: A State-Level Patchwork

In the United States, cannabis policy has reached a point where inconsistency is no longer just a flaw; it’s a failure. In one state, cannabis is a regulated product generating billions in tax revenue and supporting public programs. In another, it remains entirely illegal, even for patients with serious medical conditions. Crossing a state line can mean the difference between lawful access and criminal liability.

This is not a unified national approach, but a patchwork of contradictions that increasingly defy science, economics, and lived experience. Recent commentary from Pennsylvania, Idaho, and Missouri illustrates just how far apart the country remains and how urgently that gap needs to close.

Pennsylvania: Stalled Cannabis Policy

When it comes to cannabis legalization in the state of Pennsylvania, Governor Josh Shapiro has taken a position grounded in both fiscal reality and policy precedent:

“While some in Harrisburg claim we can’t afford to make bigger investments in our kids, public safety, and our economy, know this: If we legalized and regulated adult-use cannabis, we’d bring in $1.3 BILLION in revenue for our Commonwealth over the first five years. Those are dollars that can be invested back into our people and our communities. Stop with the excuses. Let’s get this done.”

There is a growing frustration embedded in that statement and rightfully so. Neighboring states that have legalized cannabis are no longer experimenting. They are operating established markets, collecting substantial tax revenue, and redirecting those funds into schools, infrastructure, and public safety initiatives. The data exists, the models exist, and the outcomes are measurable.

And yet, Pennsylvania remains stalled.

At this stage, the delay becomes harder to justify as anything other than political inertia. The question is no longer whether legalization can work, as it already has. The question is why a state with clear economic incentive and mounting public support continues to hesitate while others move forward.

Idaho: Misinformation Drives Cannabis Policy

If Pennsylvania reflects hesitation, Idaho represents something more concerning: a deliberate rejection of evidence. As lawmakers push back against medical cannabis, Rep. Stephanie Mickelsen stated:

“I have traveled not only this country but across the globe, and I’m here to tell you everywhere that they have legalized marijuana, you see much more homelessness, you see people that are just completely out of it, and it is not something I want to see in Idaho.”

Statements like this are not simply inaccurate; they are dangerous in their implications. There is no credible research establishing cannabis legalization as a driver of homelessness or widespread societal decline. These are complex, systemic issues tied to housing affordability, economic inequality, and gaps in mental health care. To attribute them to cannabis is to ignore the actual causes and, in doing so, avoid addressing them.

More importantly, rhetoric like this has consequences. It shapes legislation, informs public perception, and it directly impacts patients who are denied access to care based not on science, but on stigma. At a time when policymakers have access to extensive cannabis research and real-world outcomes, choosing to rely on disproven narratives is not caution, but a failure of responsibility.

Missouri: Regulation Is the Issue Not Cannabis

In Missouri, the conversation is more nuanced but still reveals gaps in understanding. On This Week in Missouri Politics, Scott Faughn joined Governor Mike Kehoe alongside Bennie Cook, Mazzie Christensen, Nick Kimble, and Jake Kroesen to discuss the growing presence of unregulated “weed.”

The panelist discussed the urgency for safety regulations to keep high-THC products out of gas stations and reduce the accessibility for children in the state of Missouri. This concern, at its core, is critical. No one is advocating for unregulated access or youth exposure. But the framing matters.

It is not cannabis that is sold freely without regulation. The products they are referring to are high-THC hemp products.  This is not evidence that cannabis itself is problematic, but that policy has not kept pace with reality. Federal loopholes have allowed intoxicating products to be sold outside the regulated cannabis system, creating confusion for consumers and challenges for enforcement.

What Missouri is experiencing is not the failure of legalization; it is the consequence of partial legalization without comprehensive regulation. When policymakers focus on restricting access rather than refining systems, they risk reinforcing the very issues they aim to solve. Hemp is a medicinal plant that helps many across the world. While it absolutely needs more regulations, it does not need blanket bans.

Looking North: Cannabis in Canada

While the United States continues to debate, Canada has already implemented full federal legalization, offering a real-world example of what a unified approach can look like. They did not approach legalization recklessly but worked diligently to build a framework centered on regulation, safety, and accountability. Products are tested, sales are controlled, age restrictions are enforced, and revenue is reinvested.

The country did not experience the societal collapse often predicted by opponents of legalization. Instead, it replaced uncertainty with structure. The contrast with the United States is difficult to ignore. While one nation in North America operates within a cohesive system, the other continues to navigate a fragmented landscape where legality changes from one state border to the next.

The Human Cost: Cannabis Medical Refugees

For me, this issue is not theoretical; it is lived experience. I had to leave Wisconsin and move to Nevada for access to medical cannabis due to the fragmented cannabis laws in the United States. I live with Ehlers-Danlos syndrome, and before I had access, my condition was rapidly worsening. My body was declining in ways that were impossible to ignore. I was bedbound and each day brought less mobility, excruciating pain, and fewer options.

Traditional pharmaceuticals were not giving me my life back. In many cases, they were compounding the problem. Cannabis changed that trajectory. It gave me a level of functionality I had been losing. It gave me a chance to participate in my own life again.

But access came at a cost, one that never should have existed. I had to leave my home and my community to access a plant that is legal in many other states, but still equal to heroin in my home state.

The harsh reality is, I am among the fortunate. There are millions of people in this country living with chronic debilitating illnesses who do not have the ability to relocate. They remain in states where access is denied, navigating pain and deterioration without options that could meaningfully improve their quality of life. Some endure, while others reach a point where the weight of that suffering becomes unbearable.

This is the part of the conversation that statistics alone cannot capture. Behind every policy decision are real people whose lives are shaped by access or the lack of it.

The Double Standard: Alcohol vs. Cannabis

Any honest discussion about cannabis policy in the United States must also address the glaring inconsistency in how other substances are treated. Alcohol is legal nationwide and is deeply embedded in social and economic structures. And yet, it is associated with addiction, long-term health complications, and significant public safety concerns, including impaired driving and violence.

Cannabis, by contrast, has never been linked to a fatal overdose and is increasingly supported by research highlighting its therapeutic potential. And still, cannabis remains restricted, debated, and in many states, inaccessible.

This disparity is not rooted in science. It is rooted in history, perception, and a reluctance to reevaluate long-standing narratives.

Final Thoughts: A Divide That No Longer Holds

The United States has reached a point where the divide on cannabis policy is no longer a reflection of uncertainty; it is a reflection of inconsistency.

We have the data, functioning models, patient experiences, and economic proof. What we lack is alignment. As long as policy continues to vary so dramatically from state to state, the consequences will persist of unequal access, missed opportunity, and preventable suffering.

At its core, this is no longer just a policy issue. It is a question of whether decisions will be guided by evidence or by outdated beliefs that no longer withstand scrutiny. For a country with the resources and information to do better, continuing down this path is not just inefficient; it is indefensible.